A multi-center pivotal, double-blind, placebo-controlled study with IPF patients on pirfenidone or nintedanib randomized to receive either PBI-4050 or a placebo

Trial Profile

A multi-center pivotal, double-blind, placebo-controlled study with IPF patients on pirfenidone or nintedanib randomized to receive either PBI-4050 or a placebo

Planning
Phase of Trial: Phase II/III

Latest Information Update: 18 Apr 2017

At a glance

  • Drugs PBI 4050 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Registrational; Therapeutic Use
  • Sponsors ProMetic Life Sciences
  • Most Recent Events

    • 18 Apr 2017 According to a ProMetic Life Sciences media release, company has recieved concurrence from the US Food and Drug Administration ("FDA") on the design of this trial.
    • 22 Feb 2017 According to a ProMetic Life Sciences media release, results from phase II study (CTP 251364) support the rationale and clinical design of this study.
    • 22 Feb 2017 According to a ProMetic Life Sciences media release, company intended to initiate this trial in Q2 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top